Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Latest From REGiMMUNE Corp.

Venturing into the Japanese investment market with Mebiopharm

In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and maintain momentum for lead pipeline projects will no doubt sound familiar to the management of any startup looking to commercialize new technology.

Cancer Neurology

Astellas moves into vaccine technology through Japanese deal

Astellas has signed an agreement with the Japanese bioventure REGiMMUNE to develop platform technology for the development and delivery of vaccines.

Dermatology Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • REGiMMUNE Corp.
  • Senior Management
  • Haru Morita, Pres. & CEO
    Reiko Namikawa, MD, PhD, SVP, Dev. & Strategy
    Teikichi Aoyagi, PhD, SVP, Chief Dev. Officer
  • Contact Info
  • REGiMMUNE Corp.
    Phone: (81) 3 3456 0820
    Tokyo Industry Trade Ctr. 607
    1-7-8 Kaigan
    Tokyo, 105-0022